PGP and neoplasm: As mentioned, the main pharmacological strategy of preclinical and clinical research, to overcome MDR and revert the resistant phenotype, is represented by the co-administration of an anticancer chemotherapy drug and P-gp substrate-inhibitor compounds, to restore the effective therapeutic concentration of the drug in the tumor-resistant cells.